Merck (MRK) Enterprise Value (2009 - 2026)
Merck (MRK) posted quarterly Enterprise Value of -$5.6 billion for Q1 2026, up 38.35% year-over-year from -$4.1 billion in Q1 2025, and up 61.07% quarter-over-quarter from -$14.5 billion in Q4 2025.
Merck (MRK) Enterprise Value (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Enterprise Value for 18 consecutive years, with -$5.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 38.35% year-over-year to -$5.6 billion; the TTM figure through Mar 2026 stood at -$5.6 billion (up 38.35% YoY), while the FY2025 annual figure was -$14.5 billion, down 6.45% from the prior year.
- Enterprise Value advanced to -$5.6 billion in Q1 2026 per MRK's latest filing, from -$14.5 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$5.6 billion in Q1 2024 and bottomed at -$18.2 billion in Q3 2025.
- Historically, Enterprise Value has averaged -$10.4 billion across 5 years, with a median of -$10.1 billion in 2022.
- Annual changes were most pronounced in 2023 — Enterprise Value jumped 46.37% — and 2024, when it slumped 93.64%.
- Merck's Enterprise Value stood at -$13.1 billion in 2022, then jumped by 46.37% to -$7.0 billion in 2023, then plunged by 93.64% to -$13.6 billion in 2024, then retreated by 6.45% to -$14.5 billion in 2025, then jumped by 61.07% to -$5.6 billion in 2026.
- Business Quant data shows MRK's Enterprise Value at -$5.6 billion in Q1 2026, -$14.5 billion in Q4 2025, and -$18.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -6.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.09 Bn |
| Mar 31, 2026 | -5.65 Bn |
| Dec 31, 2025 | -14.51 Bn |
| Sep 30, 2025 | -18.16 Bn |
| Jun 30, 2025 | -8.56 Bn |
| Mar 31, 2025 | -9.16 Bn |
| Dec 31, 2024 | -13.63 Bn |
| Sep 30, 2024 | -14.54 Bn |
| Jun 30, 2024 | -11.29 Bn |
| Mar 31, 2024 | -5.56 Bn |
| Dec 31, 2023 | -7.04 Bn |
| Sep 30, 2023 | -8.72 Bn |
| Jun 30, 2023 | -6.33 Bn |
| Mar 31, 2023 | -10.32 Bn |
| Dec 31, 2022 | -13.13 Bn |
| Sep 30, 2022 | -11.18 Bn |
| Jun 30, 2022 | -10.05 Bn |
| Mar 31, 2022 | -8.86 Bn |
| Dec 31, 2021 | -8.02 Bn |
| Sep 30, 2021 | -9.95 Bn |